Traditional HBV Vaccine

ApprovedVaccine

NNYU Langone Health

Traditional HBV Vaccine is one of 31 biologic programs targeting Hepatitis B. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

Hepatitis BApproved

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Viread

Gilead

Phase 3

4 2

Hepatitis B Vaccine

Sanofi

Phase 3

21 3

YF-Vax

Sanofi

Phase 3

1 4

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

3 5

Immunoglobulins

CSL Behring

Phase 3

1 6

Recombinant Hepatitis B Vaccine

Novartis

Phase 3

7 7

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 8

Polio Sabin.

GSK

Phase 3

1 9

B/F/TAF

Gilead

Phase 3

1 10

Traditional HBV Vaccine

NNYU Langone Health

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis B1 trial

Understanding Poor Vaccine Responses to Hepatitis B Vaccination

Active, not recruiting·NNYU Langone Health·Phase 4·NCT04674462·101 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Traditional HBV Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Traditional HBV Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Traditional HBV Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: NNYU Langone Health

Traditional HBV Vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News